Prolonged remission of refractory lymphomatoid granulomatosis after autologous hemopoietic stem cell transplantation with post-transplantation maintenance interferon

Leuk Lymphoma. 2006 Feb;47(2):323-8. doi: 10.1080/10428190500284262.

Abstract

Lymphomatoid granulomatosis (LYG) is a rare Epstein Barr virus (EBV)-associated lymphoproliferative disease. Even with combination chemotherapy, mortality is high. There is no standard therapy for relapsed or refractory disease. There is only one report in the literature of a complete remission with high-dose chemotherapy and autologous stem cell transplantation. This study presents the case of a patient with progressive LYG, who was successfully treated with autologous stem cell transplantation after conditioning with high-dose chemotherapy and total body irradiation. After transplantation, maintenance therapy with interferon alpha 2a was administered for 3.75 years. The patient remains well and in remission 8 years post-transplantation. This is the first report of a durable (>1 year) complete remission after high-dose chemotherapy and autologous stem cell transplantation in LYG. The role of high-dose chemotherapy and autologous stem cell transplantation in relapsed or refractory cases merits further evaluation. The exact place of interferon in treatment of LYG remains to be clarified but is promising.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Disease Progression
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / therapeutic use
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / therapy*
  • Lymphomatoid Granulomatosis / complications*
  • Lymphomatoid Granulomatosis / diagnosis
  • Lymphomatoid Granulomatosis / therapy*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Remission Induction / methods
  • Transplantation, Autologous
  • Treatment Outcome
  • Whole-Body Irradiation

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins